Tempus AI, Inc. (TEM)
Clinical data, diagnostics, and AI models combined into a precision-medicine platform.
Sponsored Placement Available
Sponsor this TEM page — reach investors tracking TEM
The AI Angle
Tempus AI combines molecular diagnostics, longitudinal clinical data, and machine-learning software to help physicians choose treatments and biopharma companies develop drugs. Artificial intelligence is embedded in the platform's core economics: diagnostic tests create proprietary multimodal datasets, while data licensing and modeling products turn those datasets into clinical decision support and research tools. Second-quarter 2026 revenue rose 22% to $382.5 million, with Data and Applications revenue up 28%, and management raised full-year guidance to roughly $1.6 billion. The thesis depends on sustained oncology volume, responsible expansion of its data products, and successful integration of Personalis without losing regulatory or operating discipline.
Key Numbers
Get TEM coverage in your inbox
We cover TEM and 24 other AI stocks every morning. Free daily newsletter.
Upcoming Catalysts
- Oncology diagnostic volume growth expands the clinical dataset that supports AI products
- The planned Personalis acquisition can broaden minimal-residual-disease testing and precision-oncology reach
- Data licensing and modeling demand from biopharma customers is growing faster than the diagnostics segment
- Raised 2026 revenue guidance and positive adjusted EBITDA expectations improve the operating narrative
Key Risks
- Healthcare data privacy, reimbursement, and diagnostic regulation can slow product expansion or raise compliance costs
- The Personalis acquisition introduces integration, dilution, and execution risk
- Diagnostics remain operationally intensive and may not scale like a pure software business
- Competition from diagnostics, health-data, and AI-drug-discovery platforms could pressure pricing and customer growth
Recent News
Sources: Tempus Q2 2026 results July 30, 2026; Reuters and Bloomberg Personalis coverage July 20, 2026; Yahoo Finance market data Aug. 7, 2026.
⚠️ Not financial advice. This page is for informational purposes only. All figures are sourced from public earnings reports, company guidance, and financial news. Past performance is not indicative of future results. Always do your own research before making any investment decisions.
Trade TEM with a top broker
Open a brokerage account to start trading. We may earn a commission if you use these links — see our disclosure.
Get TEM news in your inbox.
Get AI Decoded covers Tempus AI, Inc. and 24 other AI-era stocks every morning. Free daily briefing for investors.
No spam. Unsubscribe anytime. Privacy Policy